Economic evaluation of carfilzomib (car), ixazomib (ixa), elotuzumab (elo), or daratumumab (dar) with lenalidomide & dexamethasone (len+dex) vs len+dex in relapsed/refractory multiple myeloma (r/r mm)

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: ABRAHAM, Ivo (University Of Arizona, Pharmacy Practice and Science, Tucson, United States)
  • Co-author(s): Nimer Alsaid: Center for Health Outcomes and PharmacoEconomic Research, University Of Arizona College of Pharmacy, Tucson, United States
    Ali McBride: Banner University Medical Center , Tucson, United States;, University of Arizona Cancer Center, Tucson, United States
    Abdulaali Mutairi: Center for Health Outcomes and PharmacoEconomic Research, University Of Arizona College of Pharmacy, Tucson, United States
    Amit Agarwal: Banner University Medical Center, Tucson, United States;, University of Arizona Cancer Center, Tucson, United States
    Faiz Anwer: Banner University Medical Center, Tucson, United States;, University of Arizona Cancer Center, Tucson, United States
    Ivo Abraham: Center for Health Outcomes and PharmacoEconomic Research, University Of Arizona College of Pharmacy, Tucson, United States
  • Abstract:

    Background

    CAR, IXA, ELO, and DAR in triplet combination with LEN+DEX have shown superior efficacy over LEN+DEX in R/R MM, but their comparative efficacy and cost effectiveness have not been estimated.

    Purpose

    To perform cost-effectiveness and cost-utility evaluations for the four triplet regimens used in R/R MM.

    Methods

    Network meta-analysis [NMA] and ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login